Liposomes and nanotechnology in drug development: Focus on ocular targets

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 495-504

  Honda, Miki ^a   Asai, Tomohiro ^b   Oku, Naoto ^b   Araki, Yoshihiko ^c   Tanaka, Minoru ^a   Ebihara, Nobuyuki ^a  

^a JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

^c JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Age related macular degeneration; APRPG modified PEGylated liposome; DDS; Drug delivery system; Intravitreal injection

Indexed keywords

AFLIBERCEPT; AMIKACIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CYCLOSPORIN; DENDRIMER; FLOXURIDINE PHOSPHATE; FLUCONAZOLE; GANCICLOVIR; GENTAMICIN; LIPOSOME; MACROGOL; MICROSPHERE; NANOSPHERE; OFLOXACIN; OLIGONUCLEOTIDE; PEGAPTANIB; PHOSPHATIDYLGLYCEROL; POLYLACTIC ACID; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; SEMAXANIB; TACROLIMUS; TILISOLOL; TOBRAMYCIN; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VERTEPORFIN;

AREA UNDER THE CURVE; BLOOD EYE BARRIER; BLOOD RETINA BARRIER; CONTROLLED DRUG RELEASE; CYTOMEGALOVIRUS RETINITIS; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EYE LEVEL; DRUG HALF LIFE; DRUG PENETRATION; DRUG RESEARCH; DRUG RETENTION; DRUG SAFETY; DRUG TARGETING; DRUG TISSUE LEVEL; DRUQ AQUEOUS HUMOR LEVEL; DRUQ VITREOUS LEVEL; ENCAPSULATION; EYE DISEASE; FOOD AND DRUG ADMINISTRATION; HUMAN; MICROEMULSION; NANOTECHNOLOGY; NEPHROTOXICITY; NONHUMAN; POSTERIOR EYE SEGMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINOPATHY; REVIEW; SUBRETINAL NEOVASCULARIZATION; UNITED STATES; UVEITIS; UVEORETINITIS;

AGE-RELATED MACULAR DEGENERATION; APRPG-MODIFIED PEGYLATED LIPOSOME; DDS; DRUG DELIVERY SYSTEM; INTRAVITREAL INJECTION;

ANIMALS; EYE DISEASES; HUMANS; INTRAVITREAL INJECTIONS; LIPOSOMES; NANOCAPSULES; NANOMEDICINE; OPHTHALMIC SOLUTIONS;

EID: 84873942340     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S30725     Document Type: Review

References (67)

1. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today. 2003;8(24):1112-1120.
2. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12(3):348-360.
3. Liu S, Jones L, Gu FX. Nanomaterials for ocular drug delivery. Macromol Biosci. 2012;12(5):608-620.
4. Thrimawithana TR, Young S, Bunt CR, Green C, Alany RG. Drug delivery to the posterior segment of the eye. Drug Discov Today. 2011;16(5-6):270-277.
5. Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y. Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res. 2004;23(3):253-281.
6. Klyce SD, Crosson CE. Transport processes across the rabbit corneal epithelium: a review. Curr Eye Res. 1985;4(4):323-331.
7. Barar J, Javadzadeh AR, Omidi Y. Ocular novel drug delivery: impacts of membranes and barriers. Expert Opin Drug Deliv. 2008; 5(5):567-581.
8. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26(5):1197-1216.
9. Holland GN, Sakamoto MJ, Hardy D, Sidikaro Y, Kreiger AE, Frenkel LM. Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome. Use of the experimental drug 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Arch Ophthalmol. 1986;104(12):1794-1800.
10. Ussery FM 3rd, Gibson SR, Conklin RH, Piot DF, Stool EW, Conklin AJ. Intravitreal ganciclovir in the treatment of AIDSassociated cytomegalovirus retinitis. Ophthalmology. 1988;95(5): 640-648.
11. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol. 1998;43(3):245-269.
12. Leibowitz HM, Krueger DE, Maunder LR, etal. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol. 1980;24(Suppl):335-610.
13. Ishibashi T, Hata Y, Yoshikawa H, Nakagawa K, Sueishi K, Inomata H. Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 1997;235(3):159-167.
14. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37(5):855-868.
15. Yi X, Ogata N, Komada M, et al. Vascular endothelial growth factor expression in choroidal neovascularization in rats. Graefes Arch Clin Exp Ophthalmol. 1997;235(5):313-319.
16. Heinemann MH. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch Ophthalmol. 1989;107(12):1767-1772.
17. Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina. 2009;29(7):875-912.
18. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-1822.
19. Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol. 1964;8:660-668.
20. Oku N. Anticancer therapy using glucuronate modified long-circulating liposomes. Adv Drug Deliv Rev. 1999;40(1-2):63-73.
21. Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv. 2005;2(4):369-381.
22. van Rooijen N, van Nieuwmegen R. Liposomes in immunology: multilamellar phosphatidylcholine liposomes as a simple, biodegradable and harmless adjuvant without any immunogenic activity of its own. Immunol Commun. 1980;9(3):243-256.
23. Lopez-Berestein G, Mehta R, Hopfer R, Mehta K, Hersh EM, Juliano R. Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. Cancer Drug Deliv. 1983;1(1): 37-42.
24. Oku N, Nojima S, Inoue K. Selective release of non-electrolytes from liposomes upon perturbation of bilayers by temperature change or polyene antibiotics. Biochim Biophys Acta. 1980;595(2):277-290.
25. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268(1):235-237.
26. Tremblay C, Barza M, Szoka F, Lahav M, Baum J. Reduced toxicity of liposome-associated amphotericin B injected intravitreally in rabbits. Invest Ophthalmol Vis Sci. 1985;26(5):711-718.
27. Barza M, Baum J, Tremblay C, Szoka F, D'Amico DJ. Ocular toxicity of intravitreally injected liposomal amphotericin B in rhesus monkeys. Am J Ophthalmol. 1985;100(2):259-263.
28. Fishman PH, Peyman GA, Lesar T. Intravitreal liposome-encapsulated gentamicin in a rabbit model. Prolonged therapeutic levels. Invest Ophthalmol Vis Sci. 1986;27(7):1103-1106.
29. Peyman GA, Khoobehi B, Tawakol M, et al. Intravitreal injection of liposome-encapsulated ganciclovir in a rabbit model. Retina. 1987;7(4):227-229.
30. Peyman GA, Schulman JA, Khoobehi B, Alkan HM, Tawakol ME, Mani H. Toxicity and clearance of a combination of liposome-encapsulated ganciclovir and trifluridine. Retina. 1989;9(3):232-236.
31. Bochot A, Fattal E, Boutet V, etal. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest Ophthalmol Vis Sci. 2002;43(1):253-259.
32. Díaz-Llopis M, Martos MJ, España E, et al. Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients. Experimental toxicity and pharmacokinetics, and clinical trial. Doc Ophthalmol. 1992;82(4):297-305.
33. Akula SK, Ma PE, Peyman GA, et al. Treatment of cytomegalovirus retinitis with intravitreal injection of liposome encapsulated ganciclovir in a patient with AIDS. Br J Ophthalmol. 1994;78(9):677-680.
34. Zeng S, Hu C, Wei H, et al. Intravitreal pharmacokinetics of liposome-encapsulated amikacin in a rabbit model. Ophthalmology. 1993;100(11):1640-1644.
35. Cannon JP, Fiscella R, Pattharachayakul S, et al. Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model. Invest Ophthalmol Vis Sci. 2003;44(5): 2112-2117.
36. Bochot A, Couvreur P, Fattal E. Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog Retin Eye Res. 2000;19(2):131-147.
37. Abrishami M, Zarei-Ghanavati S, Soroush D, Rouhbakhsh M, Jaafari MR, Malaekeh-Nikouei B. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. Retina. 2009;29(5):699-703.
38. Alghadyan AA, Peyman GA, Khoobehi B, Liu KR. Liposome-bound cyclosporine: retinal toxicity after intravitreal injection. Int Ophthalmol. 1988;12(2):105-107.
39. Assil KK, Hartzer M, Weinreb RN, Nehorayan M, Ward T, Blumenkranz M. Liposome suppression of proliferative vitreoretinopathy. Rabbit model using antimetabolite encapsulated liposomes. Invest Ophthalmol Vis Sci. 1991;32(11):2891-2897.
40. Gariano RF, Assil KK, Wiley CA, Munguia D, Weinreb RN, Freeman WR. Retinal toxicity of the antimetabolite 5-fluorouridine 5′-monophosphate administered intravitreally using multivesicular liposomes. Retina. 1994;14(1):75-80.
41. Gupta SK, Velpandian T, Dhingra N, Jaiswal J. Intravitreal pharmacokinetics of plain and liposome-entrapped fluconazole in rabbit eyes. J Ocul Pharmacol Ther. 2000;16(6):511-518.
42. Zhang R, He R, Qian J, Guo J, Xue K, Yuan YF. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. Invest Ophthalmol Vis Sci. 2010;51(7):3575-3582.
43. Kim EK, Kim HB. Pharmacokinetics of intravitreally injected liposome-encapsulated tobramycin in normal rabbits. Yonsei Med J. 1990;31(4):308-314.
44. Lajavardi L, Bochot A, Camelo S, et al. Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal Peptide encapsulated in liposomes. Invest Ophthalmol Vis Sci. 2007;48(7):3230-3238.
45. Honda M, Asai T, Umemoto T, Araki Y, Oku N, Tanaka M. Suppression of choroidal neovascularization by intravitreal injection of liposomal SU5416. Arch Ophthalmol. 2011;129(3):317-321.
46. Kawakami S, Yamamura K, Mukai T, et al. Sustained ocular delivery of tilisolol to rabbits after topical administration or intravitreal injection of lipophilic prodrug incorporated in liposomes. J Pharm Pharmacol. 2001;53(8):1157-1161.
47. Wiechens B, Neumann D, Grammer JB, Pleyer U, Hedderich J, Duncker GI. Retinal toxicity of liposome-incorporated and free ofloxacin after intravitreal injection in rabbit eyes. Int Ophthalmol. 1998-1999;22(3):133-143.
48. Oku N, Asai T, Watanabe K, et al. Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oncogene. 2002; 21(17):2662-2669.
49. Katanasaka Y, Ida T, Asai T, et al. Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416. Cancer Lett. 2008;270(2):260-268.
50. Kawakami S, Harada A, Sakanaka K, et al. In vivo gene transfection via intravitreal injection of cationic liposome/plasmid DNA complexes in rabbits. Int J Pharm. 2004;278(2):255-262.
51. Giordano GG, Chevez-Barrios P, Refojo MF, Garcia CA. Biodegradation and tissue reaction to intravitreous biodegradable poly(D,L-lactic-coglycolic)acid microspheres. Curr Eye Res. 1995;14(9):761-768.
52. Moritera T, Ogura Y, Honda Y, Wada R, Hyon SH, Ikada Y. Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest Ophthalmol Vis Sci. 1991;32(6):1785-1790.
53. Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N Engl J Med. 1997;337(2):83-90.
54. MacCumber MW, Sadeghi S, Cohen JA, Deutsch TA. Suture loop to aid in ganciclovir implant removal. Arch Ophthalmol. 1999;117(9):1250-1254.
55. Haller JA, Bandello F, Belfort R Jr, etal; for the Ozurdex GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134-1146.
56. Lowder C, Belfort R Jr, Lightman S, et al; for the Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545-553.
57. Boyer DS, Faber D, Gupta S, et al; for the Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31(5):915-923.
58. Kimura H, Ogura Y, Moritera T, Honda Y, Tabata Y, Ikada Y. In vitro phagocytosis of polylactide microspheres by retinal pigment epithelial cells and intracellular drug release. Curr Eye Res. 1994;13(5):353-360.
59. Bourges JL, Gautier SE, Delie F, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci. 2003;44(8):3562-3569.
60. Sakurai E, Ozeki H, Kunou N, Ogura Y. Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res. 2001;33(1):31-36.
61. Yasukawa T, Tabata Y, Kimura H, Ogura Y. Recent advances in intraocular drug delivery systems. Recent Pat Drug Deliv Formul. 2011;5(1):1-10.
62. Ansari MJ, Kohli K, Dixit N. Microemulsions as potential drug delivery systems: a review. PDA J Pharm Sci Technol. 2008;62(1):66-79.
63. Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res. 2002;21(1):15-34.
64. Fialho SL, da Silva-Cunha A. New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clin Experiment Ophthalmol. 2004;32(6):626-632.
65. Quintana A, Raczka E, Piehler L, et al. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res. 2002;19(9):1310-1316.
66. Cheng Y, Xu Z, Ma M, Xu T. Dendrimers as drug carriers: applications in different routes of drug administration. J Pharm Sci. 2008;97(1):123-143.
67. Marano RJ, Wimmer N, Kearns PS, et al. Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. Exp Eye Res. 2004;79(4):525-535.